Beiersdorf Teams Up with Macro Biologics to Advance Biodegradable Antimicrobial Peptides for Enhanced Skin Care and Healthcare Solutions

Beiersdorf Teams Up with Macro Biologics to Advance Biodegradable Antimicrobial Peptides for Enhanced Skin Care and Healthcare Solutions

(IN BRIEF) Beiersdorf and Macro Biologics have announced a multi-year partnership to develop biodegradable antimicrobial peptides, aimed at advancing skin care and healthcare solutions. The collaboration will utilize Macro Biologics’ advanced antimicrobial technology, known as Amicidins, which targets a broad range of bacteria. Beiersdorf will integrate these peptides into its product lines and has also invested in Macro Biologics through its Oscar & Paul Corporate Venture Capital Unit. The partnership underscores Beiersdorf’s commitment to sustainability and innovation in its “Win with Care” strategy.

(PRESS RELEASE) HAMBURG, 5-Sep-2024 — /EuropaWire/ — A groundbreaking collaboration has been announced between Beiersdorf and Macro Biologics, Inc., marking a significant advancement in the field of antimicrobial technology. This multi-year partnership aims to leverage Macro Biologics’ cutting-edge research to develop biodegradable antimicrobial peptides, promising new solutions in skin care and healthcare.

Beiersdorf, renowned for its dedication to delivering innovative and sustainable consumer products, has joined forces with Macro Biologics to integrate their advanced antimicrobial peptides into Beiersdorf’s product development pipeline. This strategic collaboration highlights Beiersdorf’s commitment to enhancing its offerings with transformative technologies while reinforcing its focus on sustainability.

The partnership will harness Macro Biologics’ proprietary “Amicidins,” a suite of antimicrobial peptides with broad-spectrum efficacy against bacteria. These peptides are expected to play a pivotal role in advancing dermatological treatments and healthcare solutions by addressing a wide range of skin conditions and preventing wound infections through local application.

In addition to the collaborative research efforts, Beiersdorf’s Oscar & Paul Corporate Venture Capital Unit will invest in Macro Biologics, underscoring the alignment between the two companies’ visions for innovation and sustainability.

Dr. Gitta Neufang, Corporate Senior Vice President Global R&D at Beiersdorf, commented, “Our collaboration with Macro Biologics is a testament to our ongoing commitment to innovation and sustainability. This partnership will significantly enhance our ability to deliver cutting-edge, eco-friendly solutions that align with our ‘Win with Care’ strategy and Climate Care goals. We are excited to work with Macro Biologics to bring these advanced antimicrobial technologies to our consumers.”

Dr. Michael Bevilacqua, CEO and CSO of Macro Biologics, added, “We are thrilled to partner with Beiersdorf, a leader in the skin care and healthcare sectors. This collaboration represents a perfect synergy of research expertise and market knowledge. Together, we aim to develop antimicrobial peptides that not only meet the highest standards of efficacy and safety but also contribute positively to environmental sustainability.”

This alliance marks a significant step forward in the development of sustainable antimicrobial solutions, positioning both companies at the forefront of innovation in skin care and healthcare.

About Beiersdorf AG
Beiersdorf has stood for innovative skin care and pioneering skin research for over 140 years. The company headquartered in Hamburg, Germany, employes more than 22,000 people worldwide. In the fiscal year 2023 Beiersdorf generated sales of €9.5 billion and an operating result (EBIT margin excluding special factors) of €1.2 billion. Leading international brands such as NIVEA, Eucerin, La Prairie and Hansaplast are cherished by millions of people around the world every day. Renowned brands such as Aquaphor, Coppertone and Chantecaille complement the extensive portfolio in the Consumer Business Segment. Through its wholly owned subsidiary tesa
SE, Beiersdorf is a globally leading manufacturer of technical adhesive tapes and provides self-adhesive solutions to industry, craft businesses, and consumers. Guided by the purpose ‘Care Beyond Skin’, Beiersdorf pursues an ambitious sustainability agenda with the goal of net zero emissions by 2045

Additional information can be found at www.beiersdorf.com.

About Macro Biologics, Inc.
Macro Biologics, Inc., designs, patents, and produces large molecule biologics for innovative products across multiple industries – from healthcare to food & water to packaging. Amicidins, Macro Biologics’ first class of proprietary macro biologics, are purpose-built for local application to vulnerable tissues to help prevent and treat life-threatening infections. Inspired by nature, they combine physical properties, like barrier formation, with broad and effective microbicidal activity against a wide variety of bacteria (including antibiotic-resistant strains), as well as Candida spp. Importantly, Amicidins are composed of amino acids and designed to be safe for people and the environment. The company’s core principle is progress guided by nature. Macro Biologics is headquartered in Carlsbad, CA.

Additional information can be found at www.macrobiologics.com.

Media Contact:

Corporate Communications
Anke Schmidt
Tel.: +49 40 4909- 2001
E-mail: cc@beiersdorf.com

SOURCE: Beiersdorf AG